Dyne Therapeutics (DYN) Share-based Compensation (2019 - 2026)

Dyne Therapeutics' Share-based Compensation history runs 8 years deep, the most recent figure standing at $13.1 million for Q1 2026.

• In Q1 2026, Share-based Compensation changed 0.47% year-over-year to $13.1 million; the TTM figure through Mar 2026 stood at $35.5 million (up 15.48% YoY), while the FY2025 annual figure was $45.9 million, changed 0.03% from the prior year.
• Share-based Compensation was $13.1 million for Q1 2026 at Dyne Therapeutics, up from $11.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $19.9 million in Q1 2024 to a low of $100000.0 in Q2 2025.
• Historically, Share-based Compensation has averaged $7.1 million across 5 years, with a median of $4.9 million in 2023.
• Biggest YoY gain for Share-based Compensation was 2116.4% in 2025; the steepest drop was 98.52% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $3.8 million in 2022, then surged by 49.53% to $5.7 million in 2023, then surged by 82.84% to $10.5 million in 2024, then climbed by 7.15% to $11.2 million in 2025, then increased by 16.52% to $13.1 million in 2026.
• The last three Share-based Compensation figures came in at $13.1 million (Q1 2026), $11.2 million (Q4 2025), and $11.1 million (Q3 2025), per Business Quant data.